Professor of Medical Oncology, Wayne State University
Hematology
Dr. Antoinette J. Wozniak, MD
|
|
Give Review
Antoinette Wozniak is an expert in the field of Hematology. She went to University at Buffalo, School of Medicine and Biomedical Sciences. She received 1 awards: "Super Doctor". Antoinette J. Wozniak, MD is a published doctor. She published 71 publications, including: 'Randomized trial comparing cisplatin with cisplatin plus vinorelbine in the treatment of advanced non-small-cell lung cancer: a Southwest Oncology Group study.' She is registered with Medicare and accepts Medicare payments.
Publications
- A Pilot Trial of Cisplatin/Etoposide/Radiotherapy Followed by Consolidation Docetaxel and the Combination of Bevacizumab (NSC-704865) in Patients With Inoperable Local...
- Poster session 6: Saturday 6 December 2014, 08:30-12:30Location: Poster area.
- Randomized phase II trial of pemetrexed/cisplatin with or without CBP501 in patients with advanced Malignant pleural mesothelioma.
- Preclinical rationale for PI3K/Akt/mTOR pathway inhibitors as therapy for epidermal growth factor receptor inhibitor-resistant non-small-cell lung Cancer.
- Chemotherapy Outcomes by Histologic Subtypes of Non-Small-Cell Lung Cancer: Analysis of the Southwest Oncology Group Database for Antimicrotubule-Platinum Therapy.
- Challenges in the current antiangiogenic treatment paradigm for patients with non-small cell lung Cancer.
- Phase II Study of Cediranib in Patients with Malignant Pleural Mesothelioma: SWOG S0509.
- Phase II Trial of Sunitinib Maintenance Therapy After Platinum-Based Chemotherapy in Patients with Extensive-Stage Small Cell Lung Cancer.
- Comparison of platinum-based chemotherapy in patients older and younger than 70 years: an Analysis of Southwest Oncology Group Trials 9308 and 9509.
- Phase II trial of imatinib maintenance therapy after irinotecan and cisplatin in patients with c-Kit-positive, extensive-stage small-cell lung Cancer.
- Resistance to epidermal growth factor receptor tyrosine kinase inhibitors.
- Phase II trial of fenretinide (NSC 374551) in patients with recurrent small cell lung Cancer.
- Phase II study of celecoxib and docetaxel in non-small cell lung Cancer (NSCLC) patients with progression after platinum-based therapy.
- Southwest Oncology Group phase II trial (S0341) of erlotinib (OSI-774) in patients with advanced non-small cell lung Cancer and a performance status of 2.
- Mature results of a phase II trial of gemcitabine/paclitaxel given every 2 weeks in patients with advanced non-small-cell lung Cancer.
- Adjuvant treatment of non-small-cell lung Cancer: how do we improve the cure rates further?
- 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline.
- Estimating the impact of new clinical trial proven Cancer therapy and Cancer chemoprevention on population mortality: the Karnofsky Memorial lecture.
- Women at increased risk for cardiac toxicity following chemoradiation therapy for esophageal Carcinoma.
- The neurofibromatosis type 2 gene is mutated in perineurial cell Tumors: a molecular genetic study of eight cases.
- Recent advances in non-invasive axillary staging for breast Cancer.
- Activation of human neutrophils by tachykinins: effect on formyl-methionyl-leucyl-phenylalanine- and platelet-activating factor-stimulated superoxide anion production ...
- [The significance of cathepsins B and D and their inhibitors in Cancer disease].
- [A case of rapidly progressive glomerulonephritis in the course of Wegener''s granulomatosis].
- Mutations in exons 9 and 13 of KIT gene are rare events in gastrointestinal stromal Tumors. A study of 200 cases.
- Minimally-invasive treatment of intra-articular fractures of the calcaneum.
- The application of electron microscopic morphometry as a helpful method in the diagnosis of focal segmental glomerulosclerosis (FSGS) early phase. II. Clinical usefuln...
- [Accuracy of ultrasound-guided fine-needle aspiration biopsy in diagnosis of changes in thyroid nodular lesions].
- AntiCoagulation therapy for radiation-induced myelopathy.
- The effect of combined therapy on activity of cathepsin D and alpha-1-antitrypsin in the blood serum of women with cervical Cancer.
- Activity of flavone acetic acid (NSC-347512) against solid Tumors of mice.
- Neurotoxicity of antineoplastic agents.
- Activity of some lysosomal enzymes in serum and in tumors of patients with squamous cell lung Carcinoma.
- Validation of the Joensuu risk criteria for primary resectable gastrointestinal stromal tumour - the impact of tumour rupture on patient outcomes.
- Comparative molecular field Analysis of in vitro growth inhibition of L1210 and HCT-8 cells by some pyrazoloacridines.
- How does osteonecrosis about the knee progress in young patients with Leukemia?: a 2- to 7-year study.
- Antitumor efficacy of PD115934 (NSC 366140) against solid Tumors of mice.
- Single-agent vinorelbine in the treatment of non-small cell lung Cancer.
- Cyclophosphamide, methotrexate, and 5-fluorouracil in the treatment of metastatic prostate Cancer. A Southwest Oncology Group study.
- 2000 update of recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines. American Society of Clinical Onco...
- A phase I clinical trial of spicamycin derivative KRN5500 (NSC 650426) using a phase I accelerated titration "2B" design.
- A phase II study of mitomycin C, etoposide, and cisplatin in advanced non-small cell lung Cancer.
- Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non--small-cell lung Cancer: a S...
- A phase II study of weekly alternating chemotherapy in extensive-stage small cell lung Cancer.
- Chronic oral administration of CI-994: a phase 1 study.
- Lung Cancer in patients < 50 years of age: the experience of an academic multidisciplinary program.
- 5-Fluorouracil, etoposide, and cisplatin in the management of metastatic non-small cell lung Cancer.
- Phase I trial of concurrent thoracic radiation and continuous infusion cisplatin and etoposide in stage III non-small cell lung Cancer.
- Randomized trial comparing cisplatin with cisplatin plus vinorelbine in the treatment of advanced non-small-cell lung Cancer: a Southwest Oncology Group study.
- Phase I trial of Adozelesin using the treatment schedule of daily x5 every 3 weeks.
- A randomized trial of cisplatin, vinblastine, and bleomycin versus vinblastine, cisplatin, and etoposide in the treatment of advanced germ cell Tumors of the testis: a...
- Phase I pharmacokinetic study of the novel antitumor agent SR233377.
- Parameters for individualizing systemic therapy in non-small cell lung Cancer.
- Phase II study of pemetrexed and cisplatin, with chest radiotherapy followed by docetaxel in patients with stage III non-small cell lung Cancer.
- Phase II study of gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), and celecoxib, a cyclooxygenase-2 (COX-2) inhibitor, in patients...
- Phase I clinical evaluation of ZD6126, a novel vascular-targeting agent, in patients with solid Tumors.
- Response to dual blockade of epidermal growth factor receptor (EGFR) and cycloxygenase-2 in nonsmall cell lung Cancer may be dependent on the EGFR mutational status of...
- Phase II study of docetaxel and celecoxib, a cyclooxygenase-2 inhibitor, in elderly or poor performance status (PS2) patients with advanced non-small cell lung Cancer.
- Recent advances in lung Cancer: summary of presentations from the 45th annual meeting of the American Society of Clinical Oncology (2009).
- Genistein enhances the effect of epidermal growth factor receptor tyrosine kinase inhibitors and inhibits nuclear factor kappa B in nonsmall cell lung Cancer cell lines.
- Molecular analysis-based treatment strategies for the management of non-small cell lung Cancer.
- Phase I clinical trial of 5-fluoro-pyrimidinone (5FP), an oral prodrug of 5-fluorouracil (5FU).
- Phase I clinical trial of BMS-247550, a derivative of epothilone B, using accelerated titration 2B design.
- A phase I trial of daily oral 4'- N -benzoyl-staurosporine in combination with proTracted continuous infusion 5-fluorouracil in patients with advanced solid malignancies.
- Efficacy and safety of gefitinib in chemonaive patients with advanced non-small cell lung Cancer treated in an Expanded Access Program.
- Phase II study of consolidation paclitaxel after concurrent chemoradiation in poor-risk stage III non-small-cell lung Cancer: SWOG S9712.
- Single-arm, open label study of pemetrexed plus cisplatin in chemotherapy naïve patients with Malignant pleural mesothelioma: outcomes of an expanded access program.
- Multicenter, randomized, phase 2 study of zoledronic acid in combination with docetaxel and carboplatin in patients with unresectable stage IIIB or stage IV non-small ...
- Adjuvant therapy for resected non-small cell lung Cancer.
- Pemetrexed alone or in combination with cisplatin in previously treated Malignant pleural mesothelioma: outcomes from a phase IIIB expanded access program.
Schools
University At Buffalo State University Of New York School Of Medicine
SUNY Buffalo Affil Hosps
University Fla
Procedures Preformed
- Thoracentesis
Conditions Treated
- Acute Leukemia
- Adrenal Gland Cancer
- Anal and Rectal Cancer
- Anemia
- View All
Doctors Specialties
- Hematology
- Medical Oncology
- Oncology
Accepted Insurances
Awards
- Super Doctor
Education
-
University of Florida -
University at Buffalo, School of Medicine and Biomedical Sciences
Hospital
-
DMC - Detroit Receiving Hospital -
DMC Harper University Hospital
Drug Facts
| NPI NUMBER | 1225075724 | |
| NPPES Provider LastName | WOZNIAK | |
| NPPES Provider FirstName | ANTOINETTE | |
| NPPES Provider ZIPCode | 48201 | |
| NPPES Provider State | MI | |
| Specialty Description | Hematology/Oncology | |
| Total Claim Count | 486.0 | |
| Distinct Opioid Count | 2.0 | |
| Opioid Claim Count | 77.0 | |
| Percent Opioid Claims | 15.84 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1225075724 |
| Last Name Of The Provider | WOZNIAK |
| First Name Of The Provider | ANTOINETTE |
| View All |
Similar Doctors
|
|
Dr. Naushin Shareef, MD
 This Doctor is OpenDoctor Recommended.
|
|
Dr. Bernd G. Barthel, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Zaid Al-Kadhimi, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Kristin E. Hunt, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Rasna Gupta, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. David J. Debono, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Eric M. Pryor, MD |
|
|
Dr. Mhd N. Rajeh, MD |
|
|
Dr. Ben Yan, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Ravneet Thind, MD |
|
|
Dr. Lakshmi M. Das, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Malathy Kilaru, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Hirva M. Mamdani, MD |
|
|
Dr. Wederson M. Claudino, MD |
|
|
Dr. Bhaumik Patel, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Rashmi Kanagal Shamanna, MB |